ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

Core Insights - ORIC Pharmaceuticals is focusing on registrational development plans for its lead programs, ORIC-944 and ORIC-114, targeting indications with strong clinical validation and high unmet needs [1][3] - The initiation of the first Phase 3 trial for ORIC-944 in metastatic castration-resistant prostate cancer (mCRPC) is expected in the first half of 2026, while ORIC-114's registrational trials for first-line non-small cell lung cancer (NSCLC) are anticipated to start in 2026 [1][3] - The company has extended its projected cash runway into 2027, allowing for accelerated corporate milestones [2][6] Registrational Development Plans - ORIC-944 is a potent allosteric inhibitor of PRC2, with a Phase 3 trial initiation planned for mCRPC in 1H 2026 [4] - ORIC-114 is an irreversible EGFR/HER2 inhibitor, with registrational trials focused on first-line NSCLC expected to begin in 2026 [5][7] Corporate Highlights - As of December 31, 2024, ORIC had cash, cash equivalents, and investments totaling $256 million, with an extended cash runway into 2027 based on a refined operating plan [6] - Favorable enrollment trends for both ORIC-944 and ORIC-114 are expected to lead to accelerated data reporting, including dose escalation data for ORIC-944 in 1H 2025 and comprehensive NSCLC data in 2H 2025 [7]